drugset / Trial / NCT06042920

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

NCT06042920

Phase 4 Terminated 130 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Timeline

Start
2023-10-09
Primary completion
2025-04-25
Completion
2025-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule

Indications